|
|
Effect observation of Finasteride combined with Terazosin in treatment of benign prostatic hyperplasia |
HUA Wei XI Ming WAN Song ZENG Shao-cHang WAN Yue-ping |
Renal Urology Center,Huadu People′s Hospital of Guangzhou City in Guangdong Province,Guangzhou 510800,China |
|
|
Abstract Objective To study the clinical effect of finasteride combined with terazosin in treatment of benign prostatic hyperplasia.Methods A total of 120 patients with benign prostatic hyperplasia treated in our hospital from March 2015 to March 2017 were selected as the subjects.They were evenly divided into control group and treatment group by random grouping.In the control group,Terazosin was used,while in the treatment group,combination of Terazosin and Finasteride was adopted.The indexes of urodynamics including PVR,Qmaxand VMCC before and after therapy,improvement of prostate symptom and quality of life score,total effectiveness rate of BPH drug,drug-induced adverse reactions,time of urinary function return to normal and total time of medical treatment in the two groups were compared.Results In the treatment group,the improvement of PVR,Qmaxand VMCC in urodynamics,prostate symptom and quality of life before and after treatment were significantly more obvious than those in the control group,the differences were statistically significant(P<0.05).The total effectiveness rate of BPH was 91.7%,higher than 70.0%in the control group,with a statistical difference(P<0.05).The rate of drug-induced adverse reactions in the treatment group(5.0%)was less than that in the control group(18.3%),the difference was statistically significant(P<0.05).The urinary function recovery time and the total duration of treatment were both shorter than those in the control group,the difference was statistically significant(P<0.05).ConclusionFor BPH patients,application of finasteride can significantly improve the patient′s urinary function,control the symptoms,ameliorate patient′s quality of life,shorten the clinical treatment time,reduce the adverse reactions,and fundamentally improve the therapeutic effect of BPH.
|
|
|
|
|
[1] |
辛玉宏,李岱,甘日强,等.前列腺突入膀胱程度与前列腺增生症膀胱出口梗阻的相关性[J].现代泌尿外科杂志,2015,20(2):105-108.
|
[2] |
黄书满,文建国.尿动力学检查在小儿排尿功能障碍诊断中的应用研究进展[J].中华实用儿科临床杂志,2014,29(5):380-384.
|
[3] |
张一川,何乐业,龙智,等.前列腺增生症患者急性尿潴留发生的临床特点[J].中南大学学报(医学版),2012,37(3):300-304.
|
[4] |
李晓京,魏艳红,沈司京,等.非那雄胺治疗良性前列腺增生症的安全性及疗效评价[J].中国医院用药评价与分析,2016,16(1):58-62.
|
[5] |
王磊,宋健,吕文成,等.非那雄胺与特拉唑嗪治疗良性前列腺增生的临床疗效及安全性分析[J].现代中西医结合杂志,2014,23(9):967-969.
|
[6] |
赵兴,王亮,黄庆华,等.特拉唑嗪与非那雄胺联合治疗良性前列腺增生患者疗效观察[J].中国老年学杂志,2013,33(13) :3179-3180.
|
[7] |
施斌,陈昆,张志明,等.前列舒通胶囊联合非那雄胺治疗良性前列腺增生症的疗效观察[J].现代药物与临床,2016,31(4):500-503.
|
[8] |
辛涛,赵爱莲,胡强.非那雄胺片联合中药脐疗治疗良性前列腺增生的临床研究[J].中国医药指南,2015,10(15):53-55.
|
[9] |
吴成璋,李顺.盐酸特拉唑嗪联合非那雄胺片对老年良性前列腺增生患者血清TNF-α及PSA水平的影响[J].中国生化药物杂志,2016,36(4):97-99.
|
[10] |
李晓京,魏艳红,沈司京,等.非那雄胺治疗良性前列腺增生症的安全性及疗效评价[J].中国医院用药评价与分析,2016,16(1):58-62.
|
[11] |
桑琦,孙丽娜,成显黔.长期应用非那雄胺治疗良性前列腺增生临床疗效分析[J].中国医学创新,2015,12(17):141-144.
|
[12] |
陈焕清,陈玉成,符少萍,等.低剂量非那雄胺维持治疗良性前列腺增生症中远期疗效观察[J].岭南现代临床外科,2013,13(5):400-402.
|
[13] |
陈浩,张瑞,黄兴儒,等.中西药联合治疗良性前列腺增生症的优化方案研究[J].世界中西医结合杂志,2016,11(4):510-513.
|
[14] |
孙一鸣,余长飞,李岳,等.桂枝茯苓丸加味联合穴位注射治疗前列腺增生症50例临床观察[J].中医杂志,2015,56 (11):945-947.
|
[15] |
杨进华,万琪琳,王治中,等.缬沙坦和非那雄胺联合治疗高血压合并良性前列腺增生[J].中华高血压杂志,2014,21(10):954-958.
|
|
|
|